Physician
Internal Medicine
Dr. Vainutis K. Vaitkevicius, MD
|
|
Give Review
Vainutis Vaitkevicius works in the field of Internal Medicine. Vainutis Vaitkevicius is also a published doctor. He has 56 publication published. The most recent publication is: Structural alteration of p53 protein correlated to survival in patients with pancreatic adenocarcinoma.
Publications
- Chemoradiotherapy in the treatment of regional pancreatic Carcinoma: a phase II study.
- Clinicopathologic analysis of pancreatic adenoCarcinoma in African Americans and Caucasians.
- Phase II study of Baker''s antifol in advanced colorectal Cancer.
- A phase II study of cis-diamminedichloroplatinum II for advanced Breast cancer. Two dose schedules.
- Phase III comparison of the treatment of advanced gastrointestinal Cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. A Southwest Oncology Group study.
- Clinical immunologic responsiveness in malignant disease. I. Delayed hypersensitivity reaction and the effect of cytotoxic drugs.
- Phase II study of nafoxidine in the therapy for advanced renal Carcinoma.
- Cisplatin. An active drug in the treatment of disseminated gastric Cancer.
- Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenoCarcinoma.
- Phase II trial of ftorafur with mitomycin C versus ftorafur with methyl-CCNU in untreated colorectal Cancer.
- Combined therapy for Cancer of the anal canal: a preliminary report.
- Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial Carcinoma: a Southwest Oncology Group Study.
- Proceedings: Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced Breast cancer.
- Combined preoperative chemotherapy and radiation therapy for Cancer of the esophagus: the Wayne State University, Southwest Oncology group and Radiation Therapy Oncolo...
- Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy.
- 5FU infusion with mitomycin-C versus 5 FU infusion with methyl-CCNU in the treatment of advanced colon Cancer: a Southwest Oncology Group Study.
- 5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal Cancer: a Southwest Oncology Group Study.
- Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with Cancer of the esophagus.
- Adjuvant therapy in large bowel adenoCarcinoma: long-term results of a Southwest Oncology Group Study.
- Dynamic management of squamous cell Cancer of the anal canal.
- Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced Breast carcinoma.
- A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal Carcinoma.
- 5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenoCarcinoma of the exocrine pancreas: a Southwest Oncology Group Study.
- Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal Cancer: an intergroup study.
- Chemoradiotherapy of esophageal Carcinoma.
- Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model.
- Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors.
- Phase II evaluation of ftorafur in previously untreated colorectal Cancer: a Southwest Oncology Group Study.
- An orthotopic model of human pancreatic Cancer in severe combined immunodeficient mice: potential application for preclinical studies.
- Evaluation of pyrazoloacridine in patients with advanced pancreatic Carcinoma.
- Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic Carcinoma.
- Developments in the systemic therapy of pancreatic Cancer.
- Mutations in the arginine-rich protein gene (ARP) in pancreatic Cancer.
- Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal Carcinoma.
- Molecular analysis of the p53 gene in pancreatic adenoCarcinoma.
- Cost analysis of pancreatic Carcinoma treatment.
- The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenoCarcinoma.
- Relationship of family Cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma.
- Foamy gland pattern of pancreatic ductal adenoCarcinoma: a deceptively benign-appearing variant.
- Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenoCarcinoma.
- Molecular effects of taxol and caffeine on pancreatic Cancer cells.
- Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic Cancer.
- Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents.
- Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus.
- Molecular alterations associated with improved survival in pancreatic Cancer patients treated with radiation or chemotherapy.
- Clonal preservation of human pancreatic cell line derived from primary pancreatic adenoCarcinoma.
- Utility of fluorescence in situ hybridization in pancreatic ductal adenoCarcinoma.
- Structural alteration of p53 protein correlated to survival in patients with pancreatic adenoCarcinoma.
- HER-2/neu expression in pancreatic adenoCarcinoma: relation to tumor differentiation and survival.
- CD95-related apoptotic machinery is functional in pancreatic Cancer cells.
- Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic Carcinoma: a phase II study.
- Expression of inflammatory modulator COX-2 in pancreatic ductal adenoCarcinoma and its relationship to pathologic and clinical parameters.
- A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal Malignancies.
- Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic Cancer.
- Molecular mechanism(s) of actinomycin-D induced sensitization of pancreatic Cancer cells to CD95 mediated apoptosis.
Schools
JohannWolfgangGoetheUniversitaet Frankfurt Fachbereich Humanmedizin
Grace Hospital
Detroit Rec39g Hospital
Conditions Treated
- Anemia
- Breast Cancer
- Carcinoma in Situ
- Hypercoagulable State
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
- Choice Plus POS II
- Preferred PPO
- Choice Care PPO
Hospital
-
DMC - Detroit Receiving Hospital -
DMC Harper University Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Jessica L. Schering, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ahmed T. Butt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rishi K. Sharma, MD |
|
|
Dr. Mohammad Alsawah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles E. Coffey Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wasim A. Qazi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven S. Saraf, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ayesha H. Khan, MD |
|
|
Dr. David E. Sanchez Vasquez, MD |
|
|
Dr. Sara A. Serji, DO |
|
|
Dr. Mary E. Petty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Simon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip A. Philip, MD |
|
|
Dr. Aneela Mahmud, MD |
|
|
Dr. Veronica T. Sanchez, MD |
|
|
Dr. Dania Hatahet, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sayeh M. Lavasani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sameen Z. Zaidi, MD
This Doctor is OpenDoctor Recommended.
|